Riskpilot← Back to searchSign inGet full accessA/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR
A/SActiveCVR 27908047Bredgade 40Other financial service activities, except insurance and pension funding n.e.c. · NACE 6499Est. 2004— employees
Revenue 2024
—
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2024
DKK 2K
+100% vs 2023
| Revenue | — | — |
| EBITDA | DKK 0 | — |
| Net profit | DKK 2K | +100% |
| Total assets | DKK 2,5M | +0% |
| Equity | DKK 2,5M | +0% |
| Employees | — | — |
Legal name
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR
CVR number
27908047
Legal form
Aktieselskab
NACE code
6499 · Other financial service activities, except insurance and pension funding n.e.c.
Founded
2. juni 2004
Share capital
DKK 2.000.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af 2 bestyrelsesmedlemmer i forening eller af bestyrelsens formand i forening med en direktør.
Company purpose
Selskabets formål er som komplementar at deltage i K/S BI Biomedical Venture Annex I, K/S BI Biomedical Venture Annex II, K/S BI Biomedical Venture Annex III og K/S BI Biomedical Venture IV. Selskabet hæfter direkte, ubegrænset og solidarisk for K/S BI Biomedical Venture Annex I's, K/S BI Biomedical Venture Annex II's, K/S BI Biomedical Venture Annex III's og K/S BI Biomedical Venture IVs forpligtelser.
Address
Bredgade 40
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -11 | 0 | 0 | 0 | 0 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -11 | 0 | 0 | 0 | 0 |
| Net financials | -57 | -11 | -12 | 1 | 3 |
| Profit before tax | -68 | -11 | -12 | 1 | 3 |
| Tax | -21 | -4 | -3 | -0 | 1 |
| Net profit | -47 | -7 | -9 | 1 | 2 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2.499 | 2.492 | 2.483 | 2.484 | 2.487 |
| Equity | 2.499 | 2.492 | 2.483 | 2.484 | 2.486 |
| Long-term debt | 0 | 0 | 0 | 0 | 1 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 1 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
0.1%
This company
18.4%
Market median
-99% vs market
20202024
Net profit margin
200000.0%
This company
8.1%
Market median
+2469036% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AT Management | Management | 2023 |
| Former (7) | ||
KB Management | Management | 2014 – 2016 |
SF Management | Management | 2018 – 2019 |
BF Chief Executive Officer | Chief Executive Officer | 2010 – 2014 |
KH Management | Management | 2019 – 2023 |
TT Management | Management | 2009 – 2010 |
JZ Management | Management | 2004 – 2009 |
LT Management | Management | 2016 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2014 | |
| Deputy Chairman | 2025 | |
| Former (5) | ||
| Board of Directors | 2004 – 2009 | |
| Deputy Chairman | 2004 – 2008 | |
| Chairman | 2008 – 2011 | |
| Chairman | 2004 – 2008 | |
| Deputy Chairman | 2014 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2004 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BRFHOLDING A/SJYSKE BANK A/SBI HOLDING A/S
A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR (this company)Board members of A/S BI BIOMEDICAL VENTURE ANNEX KOMPLEMENTAR also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kenneth Bering Hansen | Management | 0 companies |
| Sanne Fredenslund | Management | 0 companies |
| Bo Foged | Chief Executive Officer | 0 companies |
| Kurt Hangaard | Management | 0 companies |
| Thomas Tscherning | Management | 0 companies |
| Jesper Zeuthen | Management | 0 companies |
| Ahmet Turan Kayhan | Management | 0 companies |
| Lars Thomas Gunnarsson | Management | 0 companies |
| Nils Hougaard Christensen | Board of Directors | 0 companies |
| Bjarne Thorup | Deputy Chairman | 0 companies |
| Torben Arnth Nielsen | Chairman | 0 companies |
| Niels Burtenshaw Thuesen | Chairman | 0 companies |
| Andrea Panzieri | Chairman | 0 companies |
| Allan Funk Nissen | Deputy Chairman | 0 companies |
| Mikael Kortegaard Larsen | Deputy Chairman | 0 companies |